Anterogen.Co.Ltd Past Earnings Performance
Past criteria checks 0/6
Anterogen.Co.Ltd's earnings have been declining at an average annual rate of -4.6%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 12% per year.
Key information
-4.6%
Earnings growth rate
-2.1%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 12.0% |
Return on equity | -2.0% |
Net Margin | -34.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Anterogen.Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 6,659 | -2,314 | 2,093 | 4,147 |
31 Mar 24 | 6,490 | -3,450 | 1,986 | 5,258 |
31 Dec 23 | 6,500 | -2,841 | 1,808 | 5,384 |
30 Sep 23 | 6,288 | -3,228 | 1,811 | 5,763 |
30 Jun 23 | 6,233 | -3,703 | 1,640 | 5,598 |
31 Mar 23 | 6,467 | -4,192 | 1,930 | 4,561 |
31 Dec 22 | 6,591 | -6,837 | 2,032 | 4,658 |
30 Sep 22 | 7,538 | -6,452 | 2,020 | 4,488 |
30 Jun 22 | 7,793 | -5,347 | 2,093 | 4,352 |
31 Mar 22 | 8,304 | -347 | 1,875 | 4,300 |
31 Dec 21 | 8,122 | -554 | 1,793 | 4,194 |
30 Sep 21 | 6,585 | -1,339 | 1,610 | 4,209 |
30 Jun 21 | 5,873 | 49 | 1,384 | 3,928 |
31 Mar 21 | 4,732 | -6,226 | 1,292 | 4,154 |
31 Dec 20 | 4,151 | -4,375 | 1,269 | 4,007 |
30 Sep 20 | 4,177 | -6,705 | 1,321 | 3,949 |
30 Jun 20 | 4,169 | -8,165 | 1,548 | 3,690 |
31 Mar 20 | 4,065 | -4,186 | 1,744 | 2,994 |
31 Dec 19 | 4,148 | -4,050 | 1,830 | 2,533 |
30 Sep 19 | 3,907 | 1,093 | 1,476 | 2,860 |
30 Jun 19 | 3,661 | 359 | 1,710 | 2,425 |
31 Mar 19 | 3,560 | -1,522 | 1,958 | 1,936 |
31 Dec 18 | 3,607 | -962 | 1,922 | 1,870 |
30 Sep 18 | 3,765 | -3,030 | 2,442 | 787 |
30 Jun 18 | 4,328 | -1,451 | 2,135 | 787 |
31 Mar 18 | 4,446 | -448 | 1,803 | 1,225 |
31 Dec 17 | 5,357 | 447 | 1,760 | 1,305 |
30 Sep 17 | 5,284 | 163 | 1,782 | 1,398 |
30 Jun 17 | 5,066 | -103 | 1,694 | 1,740 |
31 Mar 17 | 4,757 | -154 | 1,619 | 1,715 |
31 Dec 16 | 4,896 | 372 | 1,599 | 1,545 |
30 Sep 16 | 4,813 | 871 | 1,516 | 1,061 |
30 Jun 16 | 5,001 | 1,348 | 1,400 | 915 |
31 Mar 16 | 4,986 | 1,337 | 1,106 | 1,152 |
31 Dec 15 | 3,532 | -58 | 1,294 | 908 |
30 Sep 15 | 3,241 | -491 | 1,310 | 1,241 |
30 Jun 15 | 2,498 | -1,135 | 1,297 | 1,290 |
31 Mar 15 | 2,082 | -1,301 | 1,531 | 927 |
31 Dec 14 | 1,834 | -1,416 | 1,248 | 1,143 |
30 Sep 14 | 1,575 | -1,681 | 899 | 1,393 |
30 Jun 14 | 1,203 | -2,080 | 1,263 | 1,149 |
31 Mar 14 | 1,162 | -1,903 | 1,075 | 1,179 |
31 Dec 13 | 916 | -1,810 | 970 | 1,059 |
Quality Earnings: A065660 is currently unprofitable.
Growing Profit Margin: A065660 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A065660 is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.
Accelerating Growth: Unable to compare A065660's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A065660 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A065660 has a negative Return on Equity (-2.02%), as it is currently unprofitable.